Report Overview

The global immunoglobulin market was pegged at US$ 12.49 billion in 2021 and is expected to witness a CAGR of 7.1% during the forecast period. 

Market Fundamentals 

Immunoglobulin are Y shaped proteins used by the immune system to neutralize the effect of any foreign material such as virus, bacteria, or any pathogens. These antibodies are naturally produced by the plasma cells in natural defenses which helps fight infections and diseases. When exposed to antigens, active plasma and B cells generate immunoglobulins. These molecules are released in response to antigen exposure, enabling the immune system to detect and respond to a variety of diseases. Many ailments, including primary and secondary immunodeficiency diseases, neuromuscular illnesses, and Kawasaki disease have been treated using immunoglobulin. 

[33434]

Market Dynamics

The global immunoglobulin market is driven by rising prevalence of immunodeficiency diseases, increase in adoption of immunoglobulins as treatments, surge in geriatric population. However, high expenses required for the medications and side effects related to immunoglobulins could be a restraining factor for the global immunoglobulin market. 

Market Ecosystem

The global immunoglobulin market has been analyzed from four perspectives: by products, applications, route of administration, and region. 

Global Immunoglobulin Market By Products  

[0990]

Based on products, the global immunoglobulin market is segmented into immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), Immunoglobulin D (IgD). These agents are used in treatment of various neurological and immunological disorders. Among these, IgG is the most common class of immunoglobulin. It makes approximately 75% of serum antibodies. The IgG immunoglobulin protects against bacterial and viral infections. IgA functions to keep immunological homeostasis with the microbiota and protect the mucosal tissues against microbial invasion. IgM antibodies play a crucial role for immune control and immunological tolerance. In addition, it also acts as the first line of defense against infections for the host. Immunoglobulin E is secreted by the immune system to show a hypersensitivity. 

Global Immunoglobulin Market By Applications 

According to applications, the global immunoglobulin market is segmented into hypogammaglobulin, CIDP (Chronic Inflammatory Demyelinating polyneuropathy), immunodeficiency diseases, and myasthenia gravis. Hypogammaglobulinemia segment has dominated the market. the hypogammaglobulin, limits the production of antibodies. This disease develops as a result of an infection caused by autoimmune condition, or a cancer like multiple myeloma. Immunoglobulins are the first line of treatment for CIDP (chronic inflammatory demyelinating polyneuropathy). To lower the frequency and severity of infections, immunodeficiency illness treatment requires a sustained supply of immunoglobulin. 

Global Immunoglobulin Market by Route Of Administration

Based on route of administration, the global immunoglobulin market is segmented into intravenous and subcutaneous. The intravenous segment has accounted highest share in the global market as intravenous immunoglobulins are considered first line of treatment. Additionally, it is used to raise the level of platelets in the blood and help prevent certain infections with B-cells. When compared to intravenous treatment, immunoglobulin subcutaneous delivery is linked to a lower risk of both systemic and localized danger.

Global Immunoglobulin Market by Region

Based on region, the global immunoglobulin market has been segmented into North America, Europe, Asia Pacific, and the Rest of the WorldThe main contributor to the worldwide immunoglobulin market is North America. The high frequency of neurological and immunological illnesses in this region is one of the factors promoting the growth of the immunoglobulin market. For instance, Myasthenia Gravis (MG), an autoimmune neurological disorder, is characterised by impaired transmission at the neuromuscular junction, according to NCBI (National Center for Biotechnology Information) in May 2021. The incidence ranges from 4.1 to 30 occurrences per million person-years, whereas the prevalence rate fluctuates between 150 and 200 cases per million.  Asia-Pacific is expected to grow at a profitable rate during the forecast period. Drug companies are also investing in cutting-edge therapies like antibody-drug conjugates, in aim of providing innovative treatments which is projected to boost market expansion in the upcoming years.

Competitive Landscape

Some of the prominent players operating in the global immunoglobulin market are 

• ADMA Biologics Inc.
• Baxter International Inc. 
• Biotest AG
• Takeda Pharmaceutical Company
• CSL Limited
• Grifols S.A
• Kedrion S.P.A
• LFB S.A
• Octapharma AG
• Pfizer Inc.
• Bayer Healthcare Pharmaceuticals LLC

Strategic Developments

• In September 2021 the Center for Drug Evaluation (CDE) of China announced that Roche's CD3/CD20 bispecific antibody RO7030816 (Mosunetuzumab) has been granted clinical trial implied approval. The drug is used for the treatment of relapsed/refractory follicular lymphoma.
• In October 2021, Amgen Inc. acquired Teneobio, Inc. This acquisition will add Teneobio's unique bispecific and multispecific immunoglobulin technologies which will significantly speed up and improve the efficiency of finding and developing novel medications. Amgen has developed into one of the top independent biotechnology businesses in the world and is creating a pipeline of drugs with game-changing potential.

Frequently Asked Questions About This Report